We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Limiting Immunogenicity Can Help Secure Safety Nod on Biosimilars
Limiting Immunogenicity Can Help Secure Safety Nod on Biosimilars
January 2, 2013
Creating biosimilars that are as close to human molecules as possible is the best way to limit the risk of immunogenic reactions, an expert says, adding that immunogenicity is the FDA’s primary safety concern when evaluating biosimilars.